XML 43 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment and Geographic Area Information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment and Geographic Area Information Segment and Geographic Area Information
Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products—International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products—Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products—Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses are aggregated and reported as the Diagnostic Products segment.
Medical Devices—Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The chief operating decision maker (CODM) at Abbott is the Chief Executive Officer (CEO). The CODM primarily considers sales and operating margin to assess the performance of segments and to allocate resources, where segment operating margin profitability includes cost of products sold and operating expenses. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
Net Sales to External Customers (a)Cost of Products SoldResearch and DevelopmentSelling, General and AdministrativeOperating Earnings (a)
(in millions)202420232022202420232022202420232022202420232022202420232022
Established Pharmaceuticals$5,194 $5,066 $4,912 $(2,444)$(2,357)$(2,305)$(176)$(173)$(186)$(1,341)$(1,330)$(1,372)$1,233 $1,206 $1,049 
Nutritionals8,413 8,154 7,459 (4,532)(4,495)(4,314)(209)(204)(191)(2,167)(2,122)(2,248)1,505 1,333 706 
Diagnostics (b)9,341 9,988 16,469 (4,995)(5,264)(7,287)(656)(698)(777)(1,617)(1,593)(1,765)2,073 2,433 6,640 
Medical Devices (b)18,986 16,887 14,802 (6,408)(5,803)(4,968)(1,546)(1,362)(1,328)(4,879)(4,416)(4,070)6,153 5,306 4,436 
Total$41,934 $40,095 $43,642 $(18,379)$(17,919)$(18,874)$(2,587)$(2,437)$(2,482)$(10,004)$(9,461)$(9,456)$10,964 $10,278 $12,831 
Other16 14 11 
Net sales$41,950 $40,109 $43,653 
Corporate functions and plan benefit costs(422)(308)(509)
Net interest expense(215)(252)(375)
Share-based compensation(673)(644)(685)
Amortization of Intangible assets(1,878)(1,966)(2,013)
Other, net (c)(763)(444)(943)
Earnings before Taxes$7,013 $6,664 $8,306 
________________________________________________________
(a)In 2024, 2023 and 2022, foreign exchange unfavorably impacted net sales and operating earnings.
(b)2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
(c)
Other, net includes costs directly related to integrating acquired businesses and restructuring charges in 2024, 2023, and 2022. Charges and expenses for restructuring actions and other cost reduction initiatives were approximately $185 million in 2024, $122 million in 2023, and $265 million in 2022. Other, net also includes: in 2024, a $143 million loss on the divestiture of a non-core business, as well as intangible and IRP&D asset impairments; in 2023, charges of $100 million related to intangible asset impairments, partially offset by income arising from fair value changes in contingent consideration related to previous business acquisitions; and in 2022, charges of $176 million related to a voluntary recall within the Nutritional products segment and charges of $111 million related to the impairment of IPR&D intangible assets.
DepreciationAdditions to
Property and Equipment (d)		Total Assets
(in millions)202420232022202420232022202420232022
Established Pharmaceuticals$96 $104 $97 $183 $185 $175 $3,087 $3,118 $2,883 
Nutritionals159 155 155 382 457 251 4,404 4,270 3,625 
Diagnostics521 499 494 758 750 832 7,678 7,767 7,985 
Medical Devices343 315 311 630 604 335 9,472 9,029 7,844 
Total Reportable Segments1,119 1,073 1,057 1,953 1,996 1,593 $24,641 $24,184 $22,337 
Other221 204 197 292 213 182 
Total$1,340 $1,277 $1,254 $2,245 $2,209 $1,775 

(in millions)20242023
Total Reportable Segment Assets$24,641 $24,184 
Cash and investments8,853 8,078 
Goodwill and intangible assets29,755 32,494 
All other (e)18,165 8,458 
Total Assets$81,414 $73,214 
________________________________________________________
(d)Amounts exclude property, plant and equipment acquired through business acquisitions.
(e)
All other includes the long-term assets associated with the defined benefit plans of $5.7 billion in 2024 and $4.2 billion in 2023. In 2024, all other also includes $7.5 billion deferred tax assets for which full valuation allowances were adjusted in 2024.
Net Sales to External
Customers (f)
(in millions)202420232022
United States$16,323 $15,452 $18,142 
Germany2,539 2,345 2,340 
China2,113 2,253 2,133 
India1,817 1,750 1,649 
Switzerland1,747 1,638 1,336 
Japan1,441 1,513 1,932 
Netherlands1,124 1,074 1,111 
All Other Countries14,846 14,084 15,010 
Consolidated$41,950 $40,109 $43,653 
________________________________________________________
(f)Sales by country are based on the country that sold the product.
Long-lived assets on a geographic basis primarily include property and equipment. It excludes goodwill, intangible assets, deferred tax assets, and financial instruments. At December 31, 2024 and 2023, long-lived assets totaled $18.5 billion and $16.2 billion, respectively, and in the United States such assets totaled $10.3 billion and $8.9 billion, respectively. Long-lived asset balances associated with other countries were not material on an individual country basis in either of the two years.